Market Overview

Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook

Share:
Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s refinancing announcement on Tuesday shouldn't be celebrated by investors, at least according to Gadfly's Max Nisen.

Nisen noted Valeant's "financial wizardry" doesn't address Valeant's long-term $30 billion debt load although it may ease short-term obligations. Specifically, the company issued new debt, which will be due in 2022 and 2024. However, the proceeds will be used to satisfy debt that is maturing in the near term.

Nisen suggested the new debt raise was necessary as Valeant has "little realistic chance of growth." In fact, the company is playing a game of "music debt chairs."

Meanwhile, Valeant managed to convince its lenders to ease some of the restricts, including maintaining a certain ratio of EBITDA to interest payments. Doing so will in fact resolve one of the most "consistently irritating issues" plaguing Valeant: The company's declining business has left it dangerously close to violating those terms.

Short-Term Stability

Nevertheless, Valeant signaled to the market its operations will be more stable in the short term. But that doesn't mean the company is out of the woods, especially after billionaire hedge fund manager and vocal Valeant supporter Bill Ackman felt it was a better move to throw in the towel and accept a multi-billion dollar loss rather than sticking around at a time when Valeant's stock is close to trading in the single-digits.

Looking forward, Valeant needs to succeed in shedding assets to raise the billions of dollars that may be necessary to satisfy its debt obligations. If it fails to do so then the company can't rely on just its "sluggish" cash flows as this is needed to invest in the business and address the eroding value of its assets.

"Rearranging deck chairs on the Titanic is just as useless when the iceberg is a bit farther off," Nisen concluded.

Related Links:

Valeant's Post-Ackman Recovery Is Characterized By 'Less Money, More Problems'

Valeant's Laundry List: Products, Divestitures And Debt Load

Posted-In: Bill Ackman Bloomberg GadflyBiotech News Health Care Movers Media General Best of Benzinga

 

Related Articles (VRX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Five Below Sharply Higher After Q4 Beat

5 Biggest Price Target Changes For Thursday